Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Akebia Therapeutics, Inc. AKBA
$1.12
+$0.06 (5.66%)
На 18:00, 12 мая 2023
+525.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
208239360.00000000
-
week52high
1.20
-
week52low
0.24
-
Revenue
292602000
-
P/E TTM
-2
-
Beta
0.71314800
-
EPS
-0.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | Neutral | 16 мая 2022 г. |
| Piper Sandler | Neutral | Overweight | 31 мар 2022 г. |
| Needham | Hold | Buy | 31 мар 2022 г. |
| Mizuho | Neutral | Buy | 31 мар 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 31 мар 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Burke Steven Keith | A | 294300 | 294300 | 31 янв 2023 г. |
| Burke Steven Keith | A | 615716 | 196200 | 31 янв 2023 г. |
| Spellman David A | A | 294300 | 294300 | 31 янв 2023 г. |
| Spellman David A | A | 524799 | 196200 | 31 янв 2023 г. |
| Butler John P. | A | 875000 | 875000 | 31 янв 2023 г. |
| Butler John P. | A | 635313 | 635313 | 31 янв 2023 г. |
| Butler John P. | A | 1699372 | 293125 | 31 янв 2023 г. |
| Burke Steven Keith | D | 418016 | 1147 | 31 авг 2022 г. |
| Spellman David A | A | 200000 | 200000 | 08 июн 2022 г. |
| Spellman David A | A | 328599 | 200000 | 08 июн 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3805210 | 1495 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 2809530 | 80408 | 31 авг 2020 г. |
| SPDR S&P Biotech ETF | 2490790 | -128145 | 31 авг 2020 г. |
| iShares NASDAQ Biotechnology ETF | 1448510 | -11190 | 31 авг 2020 г. |
| iShares Russell 2000 Growth ETF | 1206630 | -11888 | 31 авг 2020 г. |
| Vanguard Extended Market Index Fund | 2005250 | -4140 | 31 июл 2020 г. |
| Fidelity Select Biotechnology Portfolio | 1525370 | -246200 | 31 июл 2020 г. |
| Vanguard Explorer Fund | 2294600 | 2294600 | 30 июн 2020 г. |
| Candriam Equities L Biotechnology | 1159350 | 385000 | 30 июн 2020 г. |
| ClearBridge Small Cap Fund | 1070000 | -70170 | 30 июн 2020 г. |
Новостная лента
Akebia Therapeutics, Inc. (AKBA) Q1 2023 Earnings Call Transcript
Seeking Alpha
08 мая 2023 г. в 10:25
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2023 Earnings Conference Call May 8, 2023 8:30 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor and Corporate Communications John Butler - Chief Executive Officer Dave Spellman - Chief Financial Officer Conference Call Participants Allison Bratzel - Piper Sandler Thomas Yip - H.C. Wainwright Operator Good day, and thank you for standing by.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 09:54
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.
4 Top Penny Stocks To Buy According To Analysts, Targets Up To 695%
PennyStocks
27 апр 2023 г. в 11:12
Analysts say these could be penny stocks to buy. Do you agree with their outlook?
Penny Stocks To Buy? 4 To Watch Now After Big News This Week
PennyStocks
03 апр 2023 г. в 12:52
Penny stocks to watch with news this week. Are they a buy now or should you avoid them entirely?
10 Hot Penny Stocks Under $1 To Watch This Week
PennyStocks
09 мар 2023 г. в 14:31
Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.